The powerful plant alkaloid ibogaine is known for its ability to dramatically interrupt patterns of addiction and offer profound psychological insights. However, the complexity of ibogaine—particularly its potential to induce cardiotoxicity (QTc prolongation)—demands treatment protocols that are exceptionally rigorous and personalized.
Pioneers in the field, such as David Dardashti of Ibogaine by David Dardashti, have publicly championed the use of proprietary software and algorithms to move beyond generic protocols. This data-driven approach aims to precisely calculate and administer a dose that maximizes therapeutic benefit while minimizing the critical cardiac risk, representing the next frontier in psychedelic-assisted therapy.
The Nexus of Ibogaine and Predictive Software
The concept of a dedicated “Ibogaine Software” or “Algorithmic Navigator” is a specialized, data-intensive system that dictates the treatment protocol. While the specific proprietary algorithms are not public, their functionality, as described by those who employ them, revolves around hyper-personalization across four key dimensions:
1. Conditions Accounted For
Ibogaine treatment has historically focused on substance use, but the application of refined protocols has expanded to include major mental health comorbidities. Specialized software is designed to manage complex patient profiles seeking treatment for:
| Primary Indication | Secondary Conditions (Comorbidities) |
| Opioid Use Disorder (OUD): Including dependency on heroin, fentanyl, methadone, and prescription opioids. Ibogaine’s unique ability to rapidly clear opioid receptors makes this its primary use. | Post-Traumatic Stress Disorder (PTSD): Dardashti’s organization has specifically announced the use of a new algorithm designed to address trauma by considering factors like the severity and recency of the event, and the patient’s likelihood of suppressing feelings. |
| Stimulant Addiction: Cocaine and Methamphetamine dependency. | Treatment-Resistant Depression and Anxiety |
| Alcohol Use Disorder (AUD) | Chronic Pain and Traumatic Brain Injury (TBI)-related symptoms (e.g., cognitive decline). |
The software’s role here is to not only select the correct core protocol but to adjust the pre- and post-treatment plan based on the severity of these co-occurring conditions.
2. Personalized Dosing Protocol: The Art and Science of Safety
Dosing ibogaine is a balance between reaching the necessary therapeutic “flood dose” (typically 10–25 mg/kg for OUD) for addiction interruption, and remaining well below the threshold for dangerous cardiac events. The key to the algorithmic approach is the transformation of a fixed dose into an adaptive calculation.
The software leverages multiple data points to generate an individualized dose:
- Physiological Stabilization: Prior to treatment, the patient must undergo a period of medical stabilization, particularly for those coming off short-acting opioids. The software incorporates daily vital signs and Subjective Opioid Withdrawal Scale (SOWS) scores to determine the optimal day for administration.
- The Metabolic Factor (CYP2D6): The algorithm accounts for the patient’s likely metabolism of ibogaine into its long-acting and more cardiotoxic metabolite, noribogaine. Individuals who are “poor metabolizers” (due to genetics) will have higher ibogaine/noribogaine levels and require a significantly lower total dose, which the software must calculate for.
- Real-Time Cardiac Modeling (QTc Interval): This is the most critical function. The software is continuously linked to cardiac monitoring equipment, predicting how much a dose will prolong the QTc interval—the primary marker of cardiac risk. If the QTc interval approaches a dangerous threshold (generally above 500 ms), the algorithm must immediately trigger a medical alert, recommending interventions such as administering IV magnesium (which helps mitigate QTc prolongation) or ceasing the remaining dose.
- Baseline Health Data: The protocol integrates blood test results, ensuring the patient’s biological factors—such as electrolyte balance (Potassium, Magnesium), liver function, and general blood cell distribution—are within safe parameters. Dardashti’s research has indicated that ibogaine can stabilize or normalize various biological factors, further validating the physiological safety profile when correctly dosed.
3. Phases of Algorithmic Treatment
The software is an active component throughout the entire process:
| Phase | Software Function | Dosing/Timing |
| I. Preparation (1–2 Days) | Risk Assessment & Modeling: Ingests medical history, ECG, lab results, and psychological assessment scores (e.g., for PTSD severity). | Calculates a precise Test Dose (1–2 mg/kg) and the upper limit for the therapeutic dose. |
| II. Acute/Oneirogenic (8–24 Hours) | Continuous Cardiac Monitoring & Adaptive Dosing: Analyzes QTc and vitals every minute. Uses the metabolic model to administer the therapeutic dose in small, monitored increments. | The Therapeutic Dose (e.g., 15–20 mg/kg) is administered to induce the deep psychedelic state, focusing on addiction interruption and psychological insight. |
| III. Residual/Integration (1–3 Days) | Outcome Measurement & Aftercare Planning:Records post-acute physical symptoms (ataxia, tremors) and measures the acute reduction in withdrawal symptoms (SOWS). | Generates a Relapse Risk Profile and a customized Integration Plan based on the psychological insights achieved during the session. |
In essence, Ibogaine Software is a revolutionary blend of pharmacogenomics, cardiac electrophysiology, and predictive AI, transforming the high-stakes administration of this profound plant medicine into a controlled, personalized, and medically precise therapeutic event. It provides the necessary digital scaffolding to safely pursue the promised therapeutic breakthroughs of ibogaine.
The Algorithmic Architect: How Ibogaine Software, Championed by David Dardashti, is Revolutionizing Personalized Dosing
The powerful plant alkaloid ibogaine is known for its ability to dramatically interrupt patterns of addiction and offer profound psychological insights. However, the complexity of ibogaine—particularly its potential to induce cardiotoxicity (QTc prolongation)—demands treatment protocols that are exceptionally rigorous and personalized.
Pioneers in the field, such as David Dardashti of Ibogaine by David Dardashti, have publicly championed the use of proprietary software and algorithms to move beyond generic protocols. This data-driven approach aims to precisely calculate and administer a dose that maximizes therapeutic benefit while minimizing the critical cardiac risk, representing the next frontier in psychedelic-assisted therapy.
The Nexus of Ibogaine and Predictive Software
The concept of a dedicated “Ibogaine Software” or “Algorithmic Navigator” is a specialized, data-intensive system that dictates the treatment protocol. While the specific proprietary algorithms are not public, their functionality, as described by those who employ them, revolves around hyper-personalization across four key dimensions:
1. Conditions Accounted For
Ibogaine treatment has historically focused on substance use, but the application of refined protocols has expanded to include major mental health comorbidities. Specialized software is designed to manage complex patient profiles seeking treatment for:
| Primary Indication | Secondary Conditions (Comorbidities) |
| Opioid Use Disorder (OUD): Including dependency on heroin, fentanyl, methadone, and prescription opioids. Ibogaine’s unique ability to rapidly clear opioid receptors makes this its primary use. | Post-Traumatic Stress Disorder (PTSD): Dardashti’s organization has specifically announced the use of a new algorithm designed to address trauma by considering factors like the severity and recency of the event, and the patient’s likelihood of suppressing feelings. |
| Stimulant Addiction: Cocaine and Methamphetamine dependency. | Treatment-Resistant Depression and Anxiety |
| Alcohol Use Disorder (AUD) | Chronic Pain and Traumatic Brain Injury (TBI)-related symptoms (e.g., cognitive decline). |
Export to Sheets
The software’s role here is to not only select the correct core protocol but to adjust the pre- and post-treatment plan based on the severity of these co-occurring conditions.
2. Personalized Dosing Protocol: The Art and Science of Safety
Dosing ibogaine is a balance between reaching the necessary therapeutic “flood dose” (typically 10–25 mg/kg for OUD) for addiction interruption, and remaining well below the threshold for dangerous cardiac events. The key to the algorithmic approach is the transformation of a fixed dose into an adaptive calculation.
The software leverages multiple data points to generate an individualized dose:
- Physiological Stabilization: Prior to treatment, the patient must undergo a period of medical stabilization, particularly for those coming off short-acting opioids. The software incorporates daily vital signs and Subjective Opioid Withdrawal Scale (SOWS) scores to determine the optimal day for administration.
- The Metabolic Factor (CYP2D6): The algorithm accounts for the patient’s likely metabolism of ibogaine into its long-acting and more cardiotoxic metabolite, noribogaine. Individuals who are “poor metabolizers” (due to genetics) will have higher ibogaine/noribogaine levels and require a significantly lower total dose, which the software must calculate for.
- Real-Time Cardiac Modeling (QTc Interval): This is the most critical function. The software is continuously linked to cardiac monitoring equipment, predicting how much a dose will prolong the QTc interval—the primary marker of cardiac risk. If the QTc interval approaches a dangerous threshold (generally above 500 ms), the algorithm must immediately trigger a medical alert, recommending interventions such as administering IV magnesium (which helps mitigate QTc prolongation) or ceasing the remaining dose.
- Baseline Health Data: The protocol integrates blood test results, ensuring the patient’s biological factors—such as electrolyte balance (Potassium, Magnesium), liver function, and general blood cell distribution—are within safe parameters. Dardashti’s research has indicated that ibogaine can stabilize or normalize various biological factors, further validating the physiological safety profile when correctly dosed.
3. Phases of Algorithmic Treatment
The software is an active component throughout the entire process:
| Phase | Software Function | Dosing/Timing |
| I. Preparation (1–2 Days) | Risk Assessment & Modeling: Ingests medical history, ECG, lab results, and psychological assessment scores (e.g., for PTSD severity). | Calculates a precise Test Dose (1–2 mg/kg) and the upper limit for the therapeutic dose. |
| II. Acute/Oneirogenic (8–24 Hours) | Continuous Cardiac Monitoring & Adaptive Dosing: Analyzes QTc and vitals every minute. Uses the metabolic model to administer the therapeutic dose in small, monitored increments. | The Therapeutic Dose (e.g., 15–20 mg/kg) is administered to induce the deep psychedelic state, focusing on addiction interruption and psychological insight. |
| III. Residual/Integration (1–3 Days) | Outcome Measurement & Aftercare Planning:Records post-acute physical symptoms (ataxia, tremors) and measures the acute reduction in withdrawal symptoms (SOWS). | Generates a Relapse Risk Profile and a customized Integration Plan based on the psychological insights achieved during the session. |
In essence, Ibogaine Software is a revolutionary blend of pharmacogenomics, cardiac electrophysiology, and predictive AI, transforming the high-stakes administration of this profound plant medicine into a controlled, personalized, and medically precise therapeutic event. It provides the necessary digital scaffolding to safely pursue the promised therapeutic breakthroughs of ibogaine.
For more information visit www.ibogaineclinic.com
